Ymmunobio
Pre-clinicalYmmunobio AG develops first-in-class therapeutics for solid tumors, targeting NPTXR, a tumor-exclusive marker found in 17+ major cancer types.
Founded
2012
Focus
AntibodiesBiologics
About
Ymmunobio AG develops first-in-class therapeutics for solid tumors, targeting NPTXR, a tumor-exclusive marker found in 17+ major cancer types.
Funding History
1Total raised: $4.2M
Seed$4.2MUndisclosedSep 15, 2021
Company Info
TypePrivate
Founded2012
LocationZurich, Switzerland
StagePre-clinical
Contact
SIMILAR COMPANIES
3Brain
Pre-clinical · Zug
Baxiva
Pre-clinical · Zug
AC Bioscience
Pre-clinical · Lausanne
Abrinca Genomics
Pre-clinical · Zurich
AdipoGen
Pre-clinical · Liestal
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile